| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192288 | Annals of Allergy, Asthma & Immunology | 2012 | 5 Pages |
Abstract
MFNS 200 μg twice daily significantly increased minimal-symptom days vs amoxicillin or placebo in patients with ARS. Results of this intranasal corticosteroids (INS) therapy indicate it can improve outcomes and potentially reduce inappropriate antibiotic use.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Eli O. MD, Davis PhD, Claus MD,